These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 20569256)

  • 1. High frequency and allele-specific differences of BRCA1 founder mutations in breast cancer and ovarian cancer patients from Belarus.
    Bogdanova NV; Antonenkova NN; Rogov YI; Karstens JH; Hillemanns P; Dörk T
    Clin Genet; 2010 Oct; 78(4):364-72. PubMed ID: 20569256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The contribution of founder mutations in BRCA1 to breast cancer in Belarus.
    Uglanitsa N; Oszurek O; Uglanitsa K; Savonievich E; Lubiński J; Cybulski C; Debniak T; Narod SA; Gronwald J
    Clin Genet; 2010 Oct; 78(4):377-80. PubMed ID: 20507347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The contribution of founder mutations in BRCA1 to breast and ovarian cancer in Lithuania.
    Elsakov P; Kurtinaitis J; Petraitis S; Ostapenko V; Razumas M; Razumas T; Meskauskas R; Petrulis K; Luksite A; Lubiński J; Górski B; Narod SA; Gronwald J
    Clin Genet; 2010 Oct; 78(4):373-6. PubMed ID: 20345474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRCA1 gene mutations may explain more than 80% of excess number of ovarian cancer cases after breast cancer - a population based study from the Western Sweden Health Care region.
    Einbeigi Z; Enerbäck C; Wallgren A; Nordling M; Karlsson P
    Acta Oncol; 2010 Apr; 49(3):361-7. PubMed ID: 20151938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The limited spectrum of pathogenic BRCA1 and BRCA2 mutations in the French Canadian breast and breast-ovarian cancer families, a founder population of Quebec, Canada].
    Tonin PN
    Bull Cancer; 2006 Sep; 93(9):841-6. PubMed ID: 16980226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A high prevalence of BRCA1 mutations among breast cancer patients from the Bahamas.
    Donenberg T; Lunn J; Curling D; Turnquest T; Krill-Jackson E; Royer R; Narod SA; Hurley J
    Breast Cancer Res Treat; 2011 Jan; 125(2):591-6. PubMed ID: 20838878
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
    Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K
    Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The prevalence of BRCA1 mutations among families at high-risk of breast and ovarian cancer in province of Malopolska between 2004-2009].
    Blecharz P; Szatkowski W; Klimek M; Urbański K
    Przegl Lek; 2009; 66(12):1046-8. PubMed ID: 20514903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRCA1 and BRCA2 point mutations and large rearrangements in breast and ovarian cancer families in Northern Poland.
    Ratajska M; Brozek I; Senkus-Konefka E; Jassem J; Stepnowska M; Palomba G; Pisano M; Casula M; Palmieri G; Borg A; Limon J
    Oncol Rep; 2008 Jan; 19(1):263-8. PubMed ID: 18097605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRCA1 genetic testing in 106 breast and ovarian cancer families from Southern Italy (Sicily): a mutation analyses.
    Russo A; Calò V; Agnese V; Bruno L; Corsale S; Augello C; Gargano G; Barbera F; Cascio S; Intrivici C; Rinaldi G; Gulotta G; Macaluso M; Surmacz E; Giordano A; Gebbia N; Bazan V
    Breast Cancer Res Treat; 2007 Nov; 105(3):267-76. PubMed ID: 17221156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
    Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
    J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ashkenazi founder BRCA1/BRCA2 mutations in Slovak hereditary breast and/or ovarian cancer families.
    Cierniková S; Tomka M; Kovác M; Stevurková V; Zajac V
    Neoplasma; 2006; 53(2):97-102. PubMed ID: 16575464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A low frequency of non-founder BRCA1 mutations in Ashkenazi Jewish breast-ovarian cancer families.
    Phelan CM; Kwan E; Jack E; Li S; Morgan C; Aubé J; Hanna D; Narod SA
    Hum Mutat; 2002 Nov; 20(5):352-7. PubMed ID: 12402332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRCA1 and BRCA2 mutations among 233 unselected Finnish ovarian carcinoma patients.
    Sarantaus L; Vahteristo P; Bloom E; Tamminen A; Unkila-Kallio L; Butzow R; Nevanlinna H
    Eur J Hum Genet; 2001 Jun; 9(6):424-30. PubMed ID: 11436123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The contribution of founder mutations to early-onset breast cancer in French-Canadian women.
    Ghadirian P; Robidoux A; Zhang P; Royer R; Akbari M; Zhang S; Fafard E; Costa M; Martin G; Potvin C; Patocskai E; Larouche N; Younan R; Nassif E; Giroux S; Narod SA; Rousseau F; Foulkes WD
    Clin Genet; 2009 Nov; 76(5):421-6. PubMed ID: 19863560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada.
    Risch HA; McLaughlin JR; Cole DE; Rosen B; Bradley L; Fan I; Tang J; Li S; Zhang S; Shaw PA; Narod SA
    J Natl Cancer Inst; 2006 Dec; 98(23):1694-706. PubMed ID: 17148771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRCA1 germline mutations and polymorphisms in a clinic-based series of ovarian cancer cases: a Gynecologic Oncology Group study.
    Smith SA; Richards WE; Caito K; Hanjani P; Markman M; DeGeest K; Gallion HH
    Gynecol Oncol; 2001 Dec; 83(3):586-92. PubMed ID: 11733976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. G1738R is a BRCA1 founder mutation in Greek breast/ovarian cancer patients: evaluation of its pathogenicity and inferences on its genealogical history.
    Anagnostopoulos T; Pertesi M; Konstantopoulou I; Armaou S; Kamakari S; Nasioulas G; Athanasiou A; Dobrovic A; Young MA; Goldgar D; Fountzilas G; Yannoukakos D
    Breast Cancer Res Treat; 2008 Jul; 110(2):377-85. PubMed ID: 17902052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of BRCA1 and BRCA2 genes in Spanish breast/ovarian cancer patients: a high proportion of mutations unique to Spain and evidence of founder effects.
    Díez O; Osorio A; Durán M; Martinez-Ferrandis JI; de la Hoya M; Salazar R; Vega A; Campos B; Rodríguez-López R; Velasco E; Chaves J; Díaz-Rubio E; Jesús Cruz J; Torres M; Esteban E; Cervantes A; Alonso C; San Román JM; González-Sarmiento R; Miner C; Carracedo A; Eugenia Armengod M; Caldés T; Benítez J; Baiget M
    Hum Mutat; 2003 Oct; 22(4):301-12. PubMed ID: 12955716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutational analysis of the BRCA1-interacting genes ZNF350/ZBRK1 and BRIP1/BACH1 among BRCA1 and BRCA2-negative probands from breast-ovarian cancer families and among early-onset breast cancer cases and reference individuals.
    Rutter JL; Smith AM; Dávila MR; Sigurdson AJ; Giusti RM; Pineda MA; Doody MM; Tucker MA; Greene MH; Zhang J; Struewing JP
    Hum Mutat; 2003 Aug; 22(2):121-8. PubMed ID: 12872252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.